Decode Age

Decode Age, based in India, specializes in longevity health solutions by offering science-backed supplements designed to promote healthy aging and overall well-being. Founded in 2021 and headquartered in Bengaluru, India, Decode Age focuses on health solutions that enhance longevity. The company has successfully completed one funding round, raising INR 144. 8 million in pre-Series A funding on December 17, 2025, aimed at expanding their biomarker programs and advancing microbiome research.

Decode Age specializes in science-backed supplements and health solutions aimed at promoting longevity and healthy aging. Their core product offerings include a range of dietary supplements that target various aspects of health, such as gut health, immunity, brain function, and skin vitality. Notably, the company is recognized for its advanced Metagenomic Gut Microbiome test and employs Next-Generation Sequencing (NGS) to conduct microbiome research. The supplements are designed for diverse customer segments, including longevity enthusiasts, wellness skeptics, and those simply interested in improving their overall health.

These products are marketed primarily within India but are also available internationally, with distribution through various e-commerce platforms like Amazon and Flipkart, allowing them to reach a broad audience seeking health optimization solutions. Decode Age operates on a direct-to-consumer model, facilitating transactions primarily through their official website and recognized e-commerce platforms. Customers typically purchase individual supplements or health bundles, with promotional offers such as seasonal discounts to encourage sales. The company has structured its revenue model around flagship products, including but not limited to, LongeVit™, Trans Resveratrol, and NMN supplements.

Each product is positioned within specific pricing tiers based on its functionality and health benefits. The revenue generation also includes potential subscriptions for ongoing health management solutions, creating a consistent income stream from repeat customers engaged in long-term health journeys. Decode Age plans to utilize its recent funding of INR 144. 8 million to support the expansion of its biomarker programs and enhance multi-omics and microbiome research.

The company is focused on strengthening its scientific infrastructure and advancing formulation studies. Moreover, Decode Age aims to foster collaborations in the longevity field, aiming for greater market presence and innovation in health solutions.